This paper is in the following e-collection/theme issue:

mHealth for Treatment Adherence (386) HIV/AIDS/STI Prevention and Care (823) Infectious Diseases (non-STD/STI) (1490) Text-messaging (SMS, WeChat etc)-Based Interventions (624)

Published on in Vol 8, No 7 (2020): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/16634, first published .
Explaining Differences in the Acceptability of 99DOTS, a Cell Phone–Based Strategy for Monitoring Adherence to Tuberculosis Medications: Qualitative Study of Patients and Health Care Providers

Explaining Differences in the Acceptability of 99DOTS, a Cell Phone–Based Strategy for Monitoring Adherence to Tuberculosis Medications: Qualitative Study of Patients and Health Care Providers

Explaining Differences in the Acceptability of 99DOTS, a Cell Phone–Based Strategy for Monitoring Adherence to Tuberculosis Medications: Qualitative Study of Patients and Health Care Providers

Authors of this article:

Beena E Thomas1 Author Orcid Image ;   J Vignesh Kumar1 Author Orcid Image ;   Chidiebere Onongaya2 Author Orcid Image ;   Spurthi N Bhatt2 Author Orcid Image ;   Amith Galivanche2 Author Orcid Image ;   Murugesan Periyasamy1 Author Orcid Image ;   M Chiranjeevi1 Author Orcid Image ;   Amit Subhash Khandewale1 Author Orcid Image ;   Geetha Ramachandran1 Author Orcid Image ;   Daksha Shah3 Author Orcid Image ;   Jessica E Haberer4 Author Orcid Image ;   Kenneth H Mayer5 Author Orcid Image ;   Ramnath Subbaraman2 Author Orcid Image
Article Authors Cited by (27) Tweetations (2) Metrics

Journals

  1. Patel D, Berger C, Kityamuwesi A, Ggita J, Kunihira Tinka L, Turimumahoro P, Feler J, Chehab L, Chen A, Gupta N, Turyahabwe S, Katamba A, Cattamanchi A, Sammann A. Iterative Adaptation of a Tuberculosis Digital Medication Adherence Technology to Meet User Needs: Qualitative Study of Patients and Health Care Providers Using Human-Centered Design Methods. JMIR Formative Research 2020;4(12):e19270 View
  2. Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, Tinka L, Nakate A, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Berger C, Tucker A, Patel D, Sammann A, Turyahabwe S, Dowdy D, Katamba A, Suthar A. Digital adherence technology for tuberculosis treatment supervision: A stepped-wedge cluster-randomized trial in Uganda. PLOS Medicine 2021;18(5):e1003628 View
  3. Subbaraman R, Thomas B, Kumar J, Thiruvengadam K, Khandewale A, Kokila S, Lubeck-Schricker M, Ranjith Kumar M, Gaurkhede G, Walgude A, Hephzibah Mercy J, Kumbhar J, Eliasziw M, Mayer K, Haberer J. Understanding Nonadherence to Tuberculosis Medications in India Using Urine Drug Metabolite Testing: A Cohort Study. Open Forum Infectious Diseases 2021;8(6) View
  4. Thomas B, Kumar J, Periyasamy M, Khandewale A, Hephzibah Mercy J, Raj E, Kokila S, Walgude A, Gaurkhede G, Kumbhar J, Ovung S, Paul M, Rajkumar B, Subbaraman R. Acceptability of the Medication Event Reminder Monitor for Promoting Adherence to Multidrug-Resistant Tuberculosis Therapy in Two Indian Cities: Qualitative Study of Patients and Health Care Providers. Journal of Medical Internet Research 2021;23(6):e23294 View
  5. Haberer J, Baijuka R, Tumuhairwe J, Tindimwebwa E, Tinkamanyire J, Tuhanamagyezi E, Musoke L, Garrison L, DelSignore M, Musinguzi N, Asiimwe S. Implementation of Electronic Adherence Monitors and Associated Interventions for Routine HIV Antiretroviral Therapy in Uganda: Promising Findings. Frontiers in Digital Health 2022;4 View
  6. Bartholomew T, Naci H, Robertson E, Schmidt H. Use of adherence monitoring in drug contracts tied to outcomes: put patients first. BMJ 2022:e062188 View
  7. Vaz C, Jose N, Tom J, Goodman G, Lee J, Padappayil R, Madathil M, O’Cleirigh C, Rodrigues R, Chai P. Formative acceptance of ingestible biosensors to measure adherence to TB medications. BMC Infectious Diseases 2022;22(1) View
  8. Needamangalam Balaji J, Prakash S, Park Y, Baek J, Shin J, Rajaguru V, Surapaneni K. A Scoping Review on Accentuating the Pragmatism in the Implication of Mobile Health (mHealth) Technology for Tuberculosis Management in India. Journal of Personalized Medicine 2022;12(10):1599 View
  9. Tadesse A, Mohammed Z, Foster N, Quaife M, McQuaid C, Levy J, van Kalmthout K, van Rest J, Jerene D, Abdurhman T, Yazew H, Umeta D, Assefa D, Weldemichael G, Bedru A, Letta T, Fielding K. Evaluation of implementation and effectiveness of digital adherence technology with differentiated care to support tuberculosis treatment adherence and improve treatment outcomes in Ethiopia: a study protocol for a cluster randomised trial. BMC Infectious Diseases 2021;21(1) View
  10. Boutilier J, Yoeli E, Rathauser J, Owiti P, Subbaraman R, Jónasson J. Can digital adherence technologies reduce inequity in tuberculosis treatment success? Evidence from a randomised controlled trial. BMJ Global Health 2022;7(12):e010512 View
  11. Mannan S, Oga-Omenka C, Soman ThekkePurakkal A, Huria L, Kalra A, Gandhi R, Kapoor T, Gunawardena N, Raj S, Kaur M, Sassi A, Pande T, Shibu V, Sarin S, Singh Chadha S, Heitkamp P, Das J, Rao R, Pai M. Adaptations to the first wave of the COVID-19 pandemic by private sector tuberculosis care providers in India. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 2022;28:100327 View
  12. Sekandi J, Kasiita V, Onuoha N, Zalwango S, Nakkonde D, Kaawa-Mafigiri D, Turinawe J, Kakaire R, Davis-Olwell P, Atuyambe L, Buregyeya E. Stakeholders’ Perceptions of Benefits of and Barriers to Using Video-Observed Treatment for Monitoring Patients With Tuberculosis in Uganda: Exploratory Qualitative Study. JMIR mHealth and uHealth 2021;9(10):e27131 View
  13. Garcia-Cremades M, Solans B, Strydom N, Vrijens B, Pillai G, Shaffer C, Thomas B, Savic R. Emerging Therapeutics, Technologies, and Drug Development Strategies to Address Patient Nonadherence and Improve Tuberculosis Treatment. Annual Review of Pharmacology and Toxicology 2022;62(1):197 View
  14. Manyazewal T, Woldeamanuel Y, Holland D, Fekadu A, Marconi V. Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial. BMC Medicine 2022;20(1) View
  15. Manyazewal T, Woldeamanuel Y, Getinet T, Hoover A, Bobosha K, Fuad O, Getahun B, Fekadu A, Holland D, Marconi V. Patient-reported usability and satisfaction with electronic medication event reminder and monitor device for tuberculosis: a multicentre, randomised controlled trial. eClinicalMedicine 2023;56:101820 View
  16. Jerene D, Levy J, van Kalmthout K, Rest J, McQuaid C, Quaife M, Charalambous S, Gamazina K, Garfin A, Mleoh L, Terleieva Y, Bogdanov A, Maraba N, Fielding K. Effectiveness of digital adherence technologies in improving tuberculosis treatment outcomes in four countries: a pragmatic cluster randomised trial protocol. BMJ Open 2023;13(3):e068685 View
  17. Chen A, Kumar R, Baria R, Shridhar P, Subbaraman R, Thies W. Impact of the 99DOTS digital adherence technology on tuberculosis treatment outcomes in North India: a pre-post study. BMC Infectious Diseases 2023;23(1) View
  18. Kiwanuka N, Kityamuwesi A, Crowder R, Guzman K, Berger C, Lamunu M, Namale C, Kunihira Tinka L, Nakate A, Ggita J, Turimumahoro P, Babirye D, Oyuku D, Patel D, Sammann A, Turyahabwe S, Dowdy D, Katamba A, Cattamanchi A, Mathur P. Implementation, feasibility, and acceptability of 99DOTS-based supervision of treatment for drug-susceptible TB in Uganda. PLOS Digital Health 2023;2(6):e0000138 View
  19. Guzman K, Crowder R, Leddy A, Maraba N, Jennings L, Ahmed S, Sultana S, Onjare B, Shilugu L, Alacapa J, Levy J, Katamba A, Kityamuwesi A, Bogdanov A, Gamazina K, Cattamanchi A, Khan A, König L. Acceptability and feasibility of digital adherence technologies for drug-susceptible tuberculosis treatment supervision: A meta-analysis of implementation feedback. PLOS Digital Health 2023;2(8):e0000322 View
  20. Guo G, Zheng Y, Ma X, Sun L, Wushouer Q, Jia B, Yusufu M, Wen S, Abudureyimu T, Peng X, Liu Z, Mamut X, Chen Y, Zhang J, Yang Y, Huangfu L, Li J, Zhang W. eDOTS: Improving the Treatment of Pulmonary Tuberculosis in Xinjiang, China. Infection and Drug Resistance 2023;Volume 16:7497 View
  21. Angelucci A, Pongiglione B, Bernasconi S, Carrone F, Mazziotti G, Costantino M, Aliverti A, Compagni A. A participatory process to design an app to improve adherence to anti-osteoporotic therapies: A development and usability study. DIGITAL HEALTH 2023;9 View
  22. Chidambaram S, Jain B, Jain U, Mwavu R, Baru R, Thomas B, Greaves F, Jayakumar S, Jain P, Rojo M, Battaglino M, Meara J, Sounderajah V, Celi L, Darzi A, Kalla M. An introduction to digital determinants of health. PLOS Digital Health 2024;3(1):e0000346 View
  23. Venkataraman A, Fatma N, Edirippulige S, Ramamohan V. Facilitators and Barriers for Telemedicine Systems in India from Multiple Stakeholder Perspectives and Settings: A Systematic Review. Telemedicine and e-Health 2024;30(5):1341 View
  24. Tadesse A, Mganga A, Dube T, Alacapa J, van Kalmthout K, Letta T, Mleoh L, Garfin A, Maraba N, Charalambous S, Foster N, Jerene D, Fielding K. Feasibility and acceptability of the smart pillbox and medication label with differentiated care to support person-centered tuberculosis care among ASCENT trial participants – A multicountry study. Frontiers in Public Health 2024;12 View
  25. Leung C, Alacapa J, Tasca B, Villanueva A, Masulit S, Ignacio M, Uy K, Pell C, van Kalmthout K, Powers R, Fielding K, Jerene D. Digital Adherence Technologies and Differentiated Care for Tuberculosis Treatment and Their Acceptability Among Persons With Tuberculosis, Health Care Workers, and Key Informants in the Philippines: Qualitative Interview Study. JMIR Human Factors 2024;11:e54117 View
  26. Zary M, Mohamed M, Kafie C, Chilala C, Bahukudumbi S, Foster N, Gore G, Fielding K, Subbaraman R, Schwartzman K. The performance of digital technologies for measuring tuberculosis medication adherence: a systematic review. BMJ Global Health 2024;9(7):e015633 View

Books/Policy Documents

  1. Fielding K, Subbaraman R, Khan A, Celan C, Charalambous S, Franke M, Huddart S, Katamba A, Law S, Stagg H. Digital Respiratory Healthcare. View